Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...

In a report released today, Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target ...

Shares of Gilead Sciences Inc. GILD inched 0.04% higher to $92.38 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.82% to 6 ...

Shares of Gilead Sciences Inc. GILD shed 1.67% to $90.59 Monday, on what proved to be an all-around dismal trading session ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Gilead Sciences, Inc. and Tubulis have announced that they have entered into an exclusive option and license agreement to ...

Justin Sullivan/Getty Images News Gilead Sciences (NASDAQ:GILD) shares logged in eight straight sessions of gains, as the ...

For years, Gilead Sciences was dead money for shareholders. Shares of the drugmaker, with a market capitalization of just ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

US antiviral giant Gilead Sciences has entered into an exclusive option and license agreement with Germany’s Tubulis to ...

Gilead Sciences (NASDAQ:GILD) shares logged in eight straight sessions of gains, as the stock closed 1.6% higher on Monday. The biopharmaceutical firm added 4.5% in the preceding seven sessions.